Partnership / Collaboration · GCC · Announced 5 May 2026

Emirates Drug Establishment → Arcera Life Sciences

The Emirates Drug Establishment and Arcera Life Sciences signed an MoU at Make it in the Emirates 2026 covering UAE pharmaceutical manufacturing, Emiratisation and supply to the national strategic stockpile.

Parties: Emirates Drug Establishment (EDE) (United Arab Emirates) → Arcera Life Sciences (United Arab Emirates)

Value
Undisclosed
Territory
United Arab Emirates
Therapeutic area
Other
Assets
Local manufacturing capacity; Strategic stockpile of medical products
Announced
5 May 2026

Our analysis

Why this matters

On 5 May 2026, the Emirates Drug Establishment (EDE) and Arcera Life Sciences announced a memorandum of understanding, signed at Make it in the Emirates (4–7 May 2026, ADNEC Abu Dhabi), to strengthen pharmaceutical manufacturing in the UAE. The framework covers local manufacturing, talent development, research and innovation, and the strategic supply of medical products. Arcera will sponsor EDE-led initiatives and create training pathways in its manufacturing facilities, and the collaboration is intended to strengthen the UAE's strategic stockpile of medical products. No products, values or timelines were disclosed.

EDE, the UAE's federal medicines regulator, has signed similar agreements with Novo Nordisk and Mubadala Bio.

The full analysis is free to read with a work email on this page.

Source: Arcera / Acino release

More deals involving Emirates Drug Establishment or Arcera Life Sciences

Latest deals

All GCC deals → · All partnership / collaboration deals → · Browse all emerging-market pharma deals →